Pharmaceutical Composition for Selective Inflammation Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic inflammation are limited due to the complexity of the underlying mechanisms involving multiple inflammation-inducing molecules, leading to inadequate differentiation between pro-inflammatory and anti-inflammatory responses, often prolonging inflammation.
Innovation Solution
A pharmaceutical composition comprising a therapeutic compound with anti-inflammatory activity, combined with a pharmaceutically acceptable adjuvant and solvent, is developed to specifically inhibit pro-inflammatory responses, thereby reducing inflammation effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current treatments for chronic inflammation are used, then inflammation can be suppressed, but anti-inflammatory responses are also blocked which prolongs inflammation
Solution Approach 1:
The invention segments the inflammatory response into pro-inflammatory and anti-inflammatory pathways, and selectively targets only the pro-inflammatory pathway. The pharmaceutical composition differentiates between these two opposing immune responses and inhibits only the harmful pro-inflammatory molecules (such as TNF-alpha, IL-1beta, IL-6) while leaving anti-inflammatory mechanisms intact. This selective segmentation resolves the contradiction by suppressing inflammation without blocking protective anti-inflammatory responses.
Solution Approach 2:
The invention applies local quality by creating a pharmaceutical composition with specific molecular targeting capabilities. The composition is designed to interact specifically with pro-inflammatory molecules at the molecular level, affecting only the harmful aspects of inflammation locally. This specificity allows inflammation suppression while preserving anti-inflammatory responses in other pathways, thus resolving the contradiction between inflammation suppression and inflammation duration.
2Object-affected harmful factors
If broad-spectrum anti-inflammatory agents are used, then inflammation can be reduced, but differentiation between pro-inflammatory and anti-inflammatory responses is lost
Solution Approach 1:
The pharmaceutical composition segments the complex inflammatory response into distinct molecular pathways. It specifically identifies and targets pro-inflammatory molecules (TNF-alpha, IL-1beta, IL-6, COX-2, LOX) while preserving anti-inflammatory mechanisms. This molecular-level segmentation enables precise differentiation between harmful and protective immune responses, resolving the contradiction between inflammation reduction and response differentiation precision.
Solution Approach 2:
The invention changes the parameter of molecular specificity in anti-inflammatory treatment. Rather than using broad-spectrum agents that affect multiple pathways, the composition is designed with specific molecular targets and binding characteristics. This parameter change in specificity allows the treatment to reduce inflammation while maintaining the ability to differentiate between pro-inflammatory and anti-inflammatory responses through selective molecular interaction.
3Object-affected harmful factors
If NSAIDs are used to block pro-inflammatory prostaglandins, then inflammation is reduced, but anti-inflammatory prostaglandins are also blocked
Solution Approach 1:
The invention segments the prostaglandin pathway into pro-inflammatory and anti-inflammatory functions. Rather than using NSAIDs that broadly inhibit cyclooxygenase and block all prostaglandin synthesis, the pharmaceutical composition selectively targets only pro-inflammatory prostaglandins and related molecules. This segmentation allows inflammation reduction while preserving the synthesis of anti-inflammatory prostaglandins, thus preventing prolonged inflammation.
Solution Approach 2:
The pharmaceutical composition applies local quality by specifically targeting pro-inflammatory prostaglandin pathways while leaving anti-inflammatory prostaglandin pathways unaffected. The composition interacts locally with specific molecular targets in the pro-inflammatory pathway, achieving inflammation reduction without the harmful side effect of blocking protective anti-inflammatory prostaglandins, thereby preventing prolonged inflammation.
Data Source
AI summary
The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.